Your browser is no longer supported. Please, upgrade your browser.
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.31 Insider Own2.50% Shs Outstand75.63M Perf Week-8.69%
Market Cap3.79B Forward P/E- EPS next Y-6.51 Insider Trans-7.56% Shs Float59.20M Perf Month-0.70%
Income-536.40M PEG- EPS next Q-0.81 Inst Own82.90% Short Float14.25% Perf Quarter48.15%
Sales0.60M P/S6316.82 EPS this Y-108.90% Inst Trans0.11% Short Ratio12.24 Perf Half Y61.03%
Book/sh1.40 P/B37.43 EPS next Y-2.70% ROA-79.00% Target Price60.79 Perf Year29.77%
Cash/sh10.07 P/C5.20 EPS next 5Y2.80% ROE-339.90% 52W Range16.85 - 58.47 Perf YTD-8.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-10.38% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low210.98% ATR2.93
Employees350 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)48.69 Volatility5.52% 4.90%
OptionableYes Debt/Eq0.00 EPS Q/Q-63.80% Profit Margin- Rel Volume1.03 Prev Close53.60
ShortableYes LT Debt/Eq3.34 EarningsNov 03 Payout- Avg Volume689.53K Price52.40
Recom1.80 SMA20-4.71% SMA508.23% SMA20046.82% Volume712,948 Change-2.24%
Nov-19-20Initiated Needham Buy $59
Sep-01-20Initiated Stifel Buy $40
Jul-20-20Initiated ROTH Capital Buy $50
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Aug-01-19Reiterated Cantor Fitzgerald Overweight $52 → $50
Jul-12-19Upgrade JP Morgan Neutral → Overweight $35 → $49
Mar-29-19Initiated Robert W. Baird Outperform $45
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Jul-30-18Upgrade B. Riley FBR Neutral → Buy $27
May-24-18Initiated Cantor Fitzgerald Overweight $52
Apr-12-18Downgrade B. Riley FBR, Inc. Buy → Neutral $27
Feb-08-18Initiated B. Riley FBR, Inc. Buy $27
Jan-07-21 06:55AM  
Jan-05-21 07:00AM  
Dec-28-20 10:00AM  
Dec-10-20 06:00AM  
Dec-07-20 10:00AM  
Dec-04-20 04:05PM  
Nov-30-20 07:00AM  
Nov-20-20 12:05PM  
Nov-19-20 06:45AM  
Nov-17-20 10:07AM  
Nov-16-20 07:00AM  
Nov-13-20 10:40AM  
Nov-11-20 07:00AM  
Nov-05-20 07:00AM  
Nov-03-20 10:29AM  
Nov-02-20 07:00AM  
Oct-27-20 10:22AM  
Oct-19-20 07:00AM  
Oct-15-20 07:00AM  
Oct-09-20 10:14AM  
Oct-07-20 04:05PM  
Oct-05-20 07:00AM  
Oct-03-20 11:05AM  
Sep-24-20 04:05PM  
Sep-21-20 04:05PM  
Sep-16-20 03:25PM  
Sep-15-20 07:00AM  
Sep-04-20 04:05PM  
Sep-02-20 07:00AM  
Sep-01-20 09:47AM  
Aug-30-20 11:30AM  
Aug-21-20 04:05PM  
Aug-07-20 04:05PM  
Jul-31-20 07:00AM  
Jul-13-20 10:31AM  
Jul-07-20 04:05PM  
Jul-02-20 08:00AM  
Jun-16-20 07:00AM  
Jun-12-20 04:23PM  
Jun-10-20 05:34PM  
Jun-05-20 04:05PM  
Jun-04-20 07:00AM  
May-29-20 04:05PM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-14-20 10:55AM  
May-08-20 07:00AM  
May-07-20 04:05PM  
Apr-29-20 04:11PM  
Apr-28-20 07:00AM  
Apr-07-20 11:33AM  
Apr-06-20 08:00AM  
Feb-27-20 04:44PM  
Feb-26-20 07:00AM  
Feb-06-20 01:23PM  
Jan-16-20 04:30PM  
Jan-15-20 05:39AM  
Jan-13-20 04:57PM  
Jan-09-20 02:18PM  
Jan-08-20 09:30PM  
Jan-07-20 04:15PM  
Jan-02-20 07:00AM  
Dec-09-19 08:48AM  
Dec-06-19 04:11PM  
Nov-26-19 07:00AM  
Nov-15-19 05:30PM  
Nov-08-19 10:00AM  
Nov-07-19 05:30PM  
Nov-05-19 07:30AM  
Oct-28-19 09:26AM  
Oct-16-19 11:43AM  
Oct-11-19 04:01PM  
Oct-04-19 05:30PM  
Oct-03-19 08:37AM  
Sep-27-19 05:30PM  
Sep-26-19 08:00AM  
Sep-18-19 08:00AM  
Sep-16-19 05:00PM  
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grossi FedericoCHIEF MEDICAL OFFICERJan 14Sale51.994,000207,96035,827Jan 15 04:10 PM
Perry Nicole DVice President - AccountingJan 04Option Exercise3.762,0007,5202,000Jan 05 04:20 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 04Sale57.2460034,34439,827Jan 05 04:21 PM
Perry Nicole DVice President - AccountingJan 04Sale57.242,000114,4800Jan 05 04:20 PM
Machiels AlecDirectorDec 15Option Exercise2.672,5006,675672,044Dec 16 04:36 PM
Machiels AlecDirectorDec 15Sale52.162,500130,400669,544Dec 16 04:36 PM
Francois CedricChief Executive OfficerDec 15Sale52.165,000260,8001,113,079Dec 16 04:35 PM
Watson David O.General CounselDec 14Option Exercise13.858,398116,31251,802Dec 15 04:03 PM
Dunlop A. SinclairDirectorDec 14Sale54.6725,0001,366,713174,728Dec 15 05:05 PM
Watson David O.General CounselDec 14Sale52.068,398437,19743,404Dec 15 04:03 PM
Watson David O.General CounselDec 11Option Exercise13.859,935137,60053,339Dec 15 04:03 PM
Watson David O.General CounselDec 11Sale50.009,935496,75043,404Dec 15 04:03 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERDec 08Option Exercise26.737,482199,99420,595Dec 09 05:34 PM
Dunlop A. SinclairDirectorDec 07Sale50.7118,564941,399199,728Dec 07 06:58 PM
Perry Nicole DVice President - AccountingDec 04Option Exercise3.7618,00067,68018,000Dec 08 07:32 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 04Option Exercise3.207,25023,20040,427Dec 08 07:21 PM
Perry Nicole DVice President - AccountingDec 04Sale50.0018,000900,0000Dec 08 07:32 PM
Dunlop A. SinclairDirectorDec 04Sale50.266,436323,455218,292Dec 07 06:58 PM
Francois CedricChief Executive OfficerDec 01Option Exercise3.7640,000150,4001,118,079Dec 02 04:31 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 01Sale48.2560028,95033,177Dec 02 04:30 PM
Machiels AlecDirectorNov 16Option Exercise2.672,5006,675672,044Nov 17 07:12 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 16Option Exercise3.205,75018,40033,777Nov 17 07:11 PM
Francois CedricChief Executive OfficerNov 16Sale39.385,000196,9001,078,079Nov 17 07:13 PM
Machiels AlecDirectorNov 16Sale39.382,50098,450669,544Nov 17 07:12 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 02Sale31.0960018,65427,725Nov 03 04:01 PM
Machiels AlecDirectorOct 15Option Exercise2.672,5006,675672,044Oct 16 05:56 PM
Machiels AlecDirectorOct 15Sale35.002,50087,500669,544Oct 16 05:56 PM
Francois CedricChief Executive OfficerOct 15Sale34.465,000172,3001,083,079Oct 16 05:31 PM
Brown Victoria L.Program Team LeadOct 07Option Exercise18.9812,000227,76015,607Oct 09 04:45 PM
Machiels AlecDirectorOct 07Option Exercise2.677,50020,025677,044Oct 09 04:48 PM
Machiels AlecDirectorOct 07Sale35.007,500262,500669,544Oct 09 04:48 PM
Brown Victoria L.Program Team LeadOct 07Sale35.0012,000420,0003,607Oct 09 04:45 PM
Grossi FedericoSee RemarksOct 01Sale30.2260018,13228,325Oct 02 04:14 PM
Francois CedricChief Executive OfficerSep 15Sale30.965,000154,8001,088,079Sep 16 04:03 PM
Grossi FedericoSee RemarksSep 01Sale31.5860018,94828,925Sep 02 04:36 PM
Francois CedricChief Executive OfficerAug 20Sale30.003,457103,7101,093,079Aug 21 04:36 PM
Francois CedricChief Executive OfficerAug 18Sale30.001,54346,2901,096,536Aug 20 04:45 PM
Grossi FedericoSee RemarksAug 03Sale26.2860015,76829,525Aug 05 04:37 PM
Francois CedricChief Executive OfficerJul 15Sale32.125,000160,6001,098,079Jul 16 04:07 PM
Grossi FedericoSee RemarksJul 01Sale32.4385027,56630,125Jul 02 05:48 PM